Page 167 WHO - Guidelines on the pharmacological treatment of persisting pain in children with medical illness

paracetamol (cont.) clinical 38–52, 84–99, 146–147
pharmaceutical profile 80–81 background 84–99
precautions 80 development process 83
versus ibuprofen in musculoskeletal trauma 105 evidence appraisal 83
paraesthesia 19 interpretation of “strong”, “weak” 84
patient controlled analgesia observational studies 83
acronym 7 Recommendation 1 38, 84–85, 146
in breakthrough pain 46 Recommendation 2 38, 86–87, 146
PCA 7 Recommendation 3 38, 86–87, 146
Peer Review Group Recommendation 4 42, 87–88, 146
acknowledgement 6 Recommendation 5 42–43, 88–89, 146
participants 142–143 Recommendation 6 42–43, 88–89, 146
permission be based on competence Recommendation 7 42–43, 88–89, 146
(Rec. 23) 59–60, 101, 147 Recommendation 8 43–44, 90–91, 146
pethidine 43 Recommendation 9 43–44, 90–91, 146
pharmacological management 10 Recommendation 10 44–45, 91–92, 146
pharmacological profile 14, 41, 63–81 Recommendation 11 44–45, 91–92, 146
fentanyl 63–66 Recommendation 12 44–45, 91–92, 146
hydromorphone 66–68 Recommendation 13 45, 92–93, 146
ibuprofen 69–70 Recommendation 14 45, 92–93, 146
methadone 70–73 Recommendation 15 45, 92–93, 146
morphine 73–76 Recommendation 16 46, 93–94, 147
naloxone 76–77 Recommendation 17 46, 93–94, 147
oxycodone 78–80 Recommendation 18 50, 95, 147
paracetamol 80–81 Recommendation 19 50–51, 95–96, 147
pharmacological treatment strategies 37, 83 reviews of randomized control trials (RCT) 83
policy-makers 13 WHO Guidelines Review Committee (GRC) 83
post-herpetic neuralgia 51 considerations of Guidelines Development Group
principles 37, 146 (GDG) 83
process (clinical guideline development) 14 corticosteroids as adjuvants (Recommendation 18)
prolonged-release morphine (Rec. 9) 43–44, 90–91, 146 50, 95, 147
psychometrics (definition) 9 distinction between breaktrhough pain and other
psychotropic substance 131 types of pain (Recommendation 16) 46, 93–94, 147
public health outcome of policies 131 education of health professionals
public-health and programme managers 13 (Recommendation 20) 59–60, 101–102, 147
Expanded Review Panel 83
Q health system 59–60, 101–102, 147
101–102
background
quality of evidence (definition) 14 Recommendation 20 59–60, 101–102, 147
Recommendation 21 59–60, 101–102, 147
R Recommendation 22 59–60, 101–102, 147
Recommendation 23 59–60, 101–102, 147
randomized controlled trial 124 immediate-release morphine (Recommendation 8)
acronym 7 43–44, 90–91, 146
RCT 7 intramuscular admininstration (Recommendation 15)
reading guide 11–12 45, 92–93, 146
recommendations 38–52, 59–60, 84–99, 101–102, involvement of professions other than physicians
146–147 and pharmacists (Recommendation 22)
alternatives to morphine (Recommendations 6 59–60, 101–102, 147
and 7) 42–43, 88–89, 146 levels of evidence 14
availability of both paracetamol and ibuprofen levels of strength 14
(Recommendation 3) 38, 86–87, 146 licensing requirements (Recommendation 21)
availibility of alternatives (Recommendation 11) 59–60, 101–102, 147
44–45, 91–92, 146 morphine as first-choice medicine
bisphosphonates as adjuvants (Recommendation 5) 42–43, 88–89, 146
(Recommendation 19) 50–51, 95–96, 147 oral administration
choice of alternative routes of admininstration (Recommendation 13) 45, 92–93, 146
(Recommendation 14) 45, 92–93, 146 permission be based on competence
(Recommendation 23) 59–60, 101–102, 147

> 164